We are live on
!
Find out more
CYTH
Cyclo Therapeutics, Inc. Common Stock
CYTH
CYTH
Delisted
CYTH was delisted on the 25th of March, 2025.
14 hedge funds and large institutions have $725K invested in Cyclo Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
12% less capital invested
Capital invested by funds: $820K → $725K (-$95.1K)
13% less funds holding
Funds holding: 16 → 14 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Holders
14
Holders Change
-2
Holders Change %
-12.5%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$61.4K |
| 2 |
Renaissance Technologies
New York
|
+$22.7K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$21.2K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.29K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$5.11K |
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$507K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.15K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.94K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.38K |
| 5 |
SSG
Summit Securities Group
New York
|
-$1K |
